Clinical Data Debuts Rituxan PGx Dx; Marks Latest Expansion of PharmaCare Alliance | GenomeWeb
Clinical Data last week debuted a gene-based test that predicts whether patients with follicular non-Hodgkin’s lymphoma will respond to monotherapy with the oncologic Rituxan.
PGxPredict: Rituximab, launched by Clinical Data’s PGx Health division, is a homebrew test that interrogates for the V158F polymorphism in the FCGR3A gene. It is designed to enable oncologists to identify whether a patient is among the 20 percent of individuals who will respond strongly to the drug, made by Genentech and Biogen Idec.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.